INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYNEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (
NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the FirmIf you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYNEW YORK, Aug. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRYNEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal RightsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (
NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (
NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (
NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (
NASDAQ: SPRY) between March 9, 2026 and June 24, 2026 inclusive (the “Class Period”). ARS Pharmaceuticals is a clinical stage biopharmaceutical company.
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options
Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action
Robbins LLP informs shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (
NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, including anaphylaxis.
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial ResultsSAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYNEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYNEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (
NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
